Remove Ablation Remove AFIB Remove Stenosis
article thumbnail

Biosense Webster Study Supports Low and Zero Fluoroscopy Workflow as Safe, Effective Alternative to Conventional Catheter Ablation

DAIC

Titled "Real-world Data Affirms Safety and Effectiveness of Low/Zero Fluoroscopy Atrial Fibrillation Ablation," the study was presented as a late-breaker at the 29th Annual International AF Symposium. Biosense Webster's zero fluoroscopy workflow is the first and only such workflow available in a radiofrequency (RF) cardiac ablation device.

Ablation 105
article thumbnail

SGLT2 Inhibitors & Aortic Valve Stenosis; Early vs. Later Ablation for Afib; Sports Participation by Athletes with Cardiac Abnormalities

American College of Cardiology

In this weeks View, Dr. Eagle looks at the potential exposure-dependent protective effect of SGLT2 inhibitors on aortic valve stenosis progression.

article thumbnail

Late-breaking Clinical Trial Results from FARADISE, adMIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for Atrial Fibrillation Treatment

DAIC

During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.

article thumbnail

Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE Platform for the Treatment of Paroxysmal Atrial Fibrillation

DAIC

The VARIPULSE Platform is comprised of the VARIPULSE Catheter, a fully integrated variable-loop multielectrode catheter; the TRUPULSE Generator, a pulsed field ablation (PFA) generator; and the CARTO 3 System VARIPULSE Software, which provides full integration with the world's leading 3D cardiac mapping system.

article thumbnail

Supercharging the ECG: AI set to Revolutionize the Diagnostic Cardiology Market

DAIC

Research is also underway into algorithms for the diagnosis of Aortic Stenosis and Myocarditis and should be ready for commercialization in the next 18 – 36 months. Fertile Partnerships Ongoing research partnerships have driven much of recent developments seen in the market.

AFIB 105
article thumbnail

Best of cardiology in 2024 : Check it out and find the winner.

Dr. S. Venkatesan MD

Top 10 Clinical Trials Preventive PCI on Stenosis With Functionally Insignificant Vulnerable Plaque PREVENT (ACC.24) Top 10 Clinical Trials Preventive PCI on Stenosis With Functionally Insignificant Vulnerable Plaque PREVENT (ACC.24) 24) Microaxial Flow Pump in Infarct-Related Cardiogenic Shock DanGer Shock (ACC.24)